Enterprise Value

543.6M

Cash

546.5M

Avg Qtr Burn

-39.87M

Short % of Float

17.61%

Insider Ownership

12.42%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Birtamimab Details
Rare diseases, Amyloid light chain amyloidosis

Phase 3

Data readout

NNC6019 (PRX004) Details
Rare diseases, Transthyretin amyloidosis

Phase 2/3

Data readout

Prasinezumab (alpha-synuclein) Details
Parkinson's disease, Neurodegenerative disease

Phase 2

Data readout

Phase 2

Initiation

Phase 1

Update

PRX123 Details
Alzheimer's disease

Phase 1

Initiation